Oncternal Price To Sales Ratio from 2010 to 2024
| ONCT Stock | USD 0.71 0.43 37.72% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 40.14878981 | Current Value 38.14 | Quarterly Volatility 1.2 K |
Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.8 M, Interest Expense of 847.7 K or Other Operating Expenses of 36.2 M, as well as many indicators such as Price To Sales Ratio of 38.14, Dividend Yield of 1.0E-4 or PTB Ratio of 1.0. Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.
Oncternal | Price To Sales Ratio |
Latest Oncternal Therapeutics' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Oncternal Therapeutics over the last few years. Price to Sales Ratio is figured by comparing Oncternal Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Oncternal Therapeutics sales, a figure that is much harder to manipulate than other Oncternal Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Oncternal Therapeutics' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncternal Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.97 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Oncternal Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 233.44 | |
| Coefficient Of Variation | 501.77 | |
| Mean Deviation | 737.66 | |
| Median | 29.48 | |
| Standard Deviation | 1,171 | |
| Sample Variance | 1.4M | |
| Range | 3.9K | |
| R-Value | (0.20) | |
| Mean Square Error | 1.4M | |
| R-Squared | 0.04 | |
| Significance | 0.48 | |
| Slope | (52.10) | |
| Total Sum of Squares | 19.2M |
Oncternal Price To Sales Ratio History
About Oncternal Therapeutics Financial Statements
Oncternal Therapeutics shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Oncternal Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Oncternal Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Oncternal Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 40.15 | 38.14 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.